ReviewWorld journal of gastrointestinal pathophysiology2014
Use of probiotics in the fight against Helicobacter pylori.
Review in World journal of gastrointestinal pathophysiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis.Medicine · 2019Pooled it
- Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials.PloS one · 2016Pooled it
- Trial
- Trial
- Is there a value for probiotic supplements in gestational diabetes mellitus? A randomized clinical trial.Journal of health, population, and nutrition · 2015Trial
- From Laboratory to Real Clinical Practice: A Multidisciplinary Approach Towards the Next Probiotics.Antibiotics (Basel, Switzerland) · 2026Article
- South African Honey: Anti-International journal of food science · 2026Article
- Novel anti-virulence strategy againstFrontiers in microbiology · 2026Article
- Therapeutic Role of Probiotics for the Treatment of Dyspepsia: A Review of the Literature.Neurogastroenterology and motility · 2025Review
- The Influence of Gastric Microbiota and Probiotics inBiomedicines · 2024Review
- Efficacy and safety of low-dose tetracycline, amoxicillin quadruple therapy inWorld journal of gastroenterology · 2024Article
- Simultaneous application of oral and intravaginal probiotics for Helicobacter pylori and its antibiotic-therapy-induced vaginal dysbacteriosis.NPJ biofilms and microbiomes · 2024Review
- The Anti-Helicobacter pylori effects of Limosilactobacillus reuteri strain 2892 isolated from Camel milk in C57BL/6 mice.World journal of microbiology & biotechnology · 2023Article
- Lacticaseibacillus casei T1 attenuates Helicobacter pylori-induced inflammation and gut microbiota disorders in mice.BMC microbiology · 2023Article
- Multidrug resistance inFrontiers in microbiology · 2023Review
- The Importance of Accurate Early Diagnosis and Eradication inAntibiotics (Basel, Switzerland) · 2022Review
- The Challenges of Eradicating PediatricChildren (Basel, Switzerland) · 2022Review
- Effects of Quadruple Therapy Combined with Probiotics onComputational and mathematical methods in medicine · 2022Article
- Editorial:Frontiers in microbiology · 2022Article
- Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections.BMC gastroenterology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After the discovery of Helicobacter pylori (H. pylori), and the evidence of its relationship with gastric diseases, antibiotic-based therapies were developed, which efficacy was however limited by antibiotic resistance and lack of patient compliance. A vaccine would overcome these drawbacks, but currently there is not any H. pylori vaccine licensed. In the frame of the studies aimed at finding alternative therapies or at increasing the efficacy of the current ones and/or reducing their side effects, the investigation on the use of probiotics plays an interesting role. In vitro and preclinical studies have shown the feasibility of this approach. Several clinical trials indicated that administration of probiotics can reduce the side effects of H. pylori eradication treatment, increasing tolerability, and often increases the overall efficacy. The results of these trials vary, likely reflecting the variety of probiotics assessed and that of the eradication treatment, as well as the differences in the geographic area that imply different H. pylori strains distribution, host susceptibility, and therapy efficacy. In conclusion, the use of probiotics appears promising as an adjuvant for the current H. pylori eradication treatment, though it still requires optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.